Insight Molecular director reports RSU tax withholding

Insight Molecular Diagnostics Inc. director Andrew J. Last reported a routine tax-withholding transaction related to equity compensation.

Rhea-AI Filing Summary

Insight Molecular Diagnostics Inc. director Andrew J. Last reported a routine tax-withholding transaction related to equity compensation. On the vesting of 35,000 restricted stock units granted on July 1, 2025, the company withheld 7,700 shares of common stock at a value of $5.69 per share to cover tax obligations. This was not an open-market sale, and the reporting person did not sell any shares. After this withholding, Last directly holds 58,752 shares of common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 7,700 shares

Exercise Price or Tax Liability 1 txn

Insider Last Andrew J.

Role Director

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock, no par value	7,700	$5.69	$44K

Holdings After Transaction: Common Stock, no par value — 58,752 shares (Direct)

Footnotes (1)

1. F1. The reported disposition reflects shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of 35,000 shares of restricted stock units granted to the reporting person on July 1, 2025. The reporting person did not sell any shares. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.

Key Figures

Shares withheld for taxes: 7,700 shares Per-share value for withholding: $5.69 per share RSUs vested: 35,000 units +1 more

4 metrics

Shares withheld for taxes 7,700 shares Withheld to cover tax obligations on RSU vesting

Per-share value for withholding $5.69 per share Nasdaq Capital Market price on vesting date

RSUs vested 35,000 units Restricted stock units granted July 1, 2025, that vested

Shares owned after transaction 58,752 shares Director’s direct common stock holdings post-withholding

Key Terms

restricted stock units, tax withholding obligations, Nasdaq Capital Market

3 terms

restricted stock units financial

"in connection with the vesting of 35,000 shares of restricted stock units granted to the reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting"

Nasdaq Capital Market market

"price per share on the date on which the shares vested as reported on the Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Insight Molecular Diagnostics (IMDX) disclose on this Form 4?

Insight Molecular Diagnostics reported that director Andrew J. Last had 7,700 shares of common stock withheld to cover tax obligations on vested restricted stock units. This is a tax-withholding disposition, not an open-market sale of shares.

Did the Insight Molecular Diagnostics (IMDX) director actually sell any shares in this filing?

No, the director did not sell any shares. The filing states the 7,700 shares were withheld by the company solely to satisfy tax withholding obligations tied to RSU vesting, rather than being sold in the market.

How many Insight Molecular Diagnostics (IMDX) restricted stock units vested for the director?

A total of 35,000 restricted stock units vested for the reporting person. The company withheld 7,700 of the resulting shares for tax obligations, while the remaining vested shares increased the director’s direct equity holdings in the company.

What is the director’s Insight Molecular Diagnostics (IMDX) share ownership after this Form 4 transaction?

Following the tax-withholding disposition, the director directly owns 58,752 shares of Insight Molecular Diagnostics common stock. This figure reflects the net position after the company withheld 7,700 shares to cover tax liabilities on vested RSUs.

At what price were the withheld Insight Molecular Diagnostics (IMDX) shares valued?

The withheld 7,700 shares were valued at $5.69 per share. The filing explains this per-share value equals the Nasdaq Capital Market price on the RSU vesting date, which is used to calculate the tax-withholding amount.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 08:38 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Last Andrew J.

(Last) (First) (Middle)

C/O INSIGHT MOLECULAR DIAGNOSTICS INC.

2 INTERNATIONAL PLAZA, SUITE 510

(Street)

NASHVILLE TENNESSEE 37217

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Insight Molecular Diagnostics Inc. [ IMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, no par value(1)	07/01/2026		F		7,700	D	$5.69	58,752	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported disposition reflects shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of 35,000 shares of restricted stock units granted to the reporting person on July 1, 2025. The reporting person did not sell any shares. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.

	/s/ Andrew J. Last	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)